NervGen Pharma Corp.
NGEN
$2.13
-$0.06-2.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.60% | -4.63% | 26.88% | -39.07% | 68.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.67% | 28.79% | -5.51% | -15.44% | 6.63% |
| Operating Income | -83.67% | -28.79% | 5.51% | 15.44% | -6.63% |
| Income Before Tax | -212.64% | 56.20% | -213.86% | 22.29% | -15.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -212.64% | 56.20% | -213.86% | 22.29% | -15.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -212.64% | 56.20% | -213.86% | 22.29% | -15.05% |
| EBIT | -83.67% | -28.79% | 5.51% | 15.44% | -6.63% |
| EBITDA | -83.86% | -28.85% | 5.50% | 15.46% | -6.66% |
| EPS Basic | -143.44% | 61.18% | -198.75% | 25.63% | -11.74% |
| Normalized Basic EPS | -143.18% | 61.32% | -198.91% | 25.43% | -11.94% |
| EPS Diluted | -176.06% | -57.42% | -198.75% | 25.63% | -14.91% |
| Normalized Diluted EPS | -142.31% | 61.73% | -198.91% | 25.43% | -11.94% |
| Average Basic Shares Outstanding | 28.47% | 13.07% | 5.03% | 4.41% | 2.87% |
| Average Diluted Shares Outstanding | 28.95% | 14.43% | 5.03% | 4.41% | 2.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |